norfloxacin has been researched along with Peritonitis in 65 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 9.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 9.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "Our aim was to compare weekly rufloxacin with daily norfloxacin in the secondary prophylaxis of spontaneous bacterial peritonitis and to examine changes in antibiotic susceptibility in fecal Escherichia coli." | 9.10 | Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. ( Bauer, TM; Bory, F; Clemente, G; Follo, A; Navasa, M; Planas, R; Rodés, J; Vaquer, P; Vargas, V; Vila, J, 2002) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 9.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| "For recipients who have received prophylactic norfloxacin, clinicians should be aware of the high risk of multidrug-resistant bacterial infections during the first month after liver transplant." | 8.31 | Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period. ( Castells, L; Dopazo, C; Len, O; Lladó, L; Los-Arcos, I; Lung, M; Nuvials, X; Oriol, I; Pérez-Cameo, C; Sabé, N, 2023) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 7.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| "Although norfloxacin (N) is widely accepted as the drug of choice for spontaneous bacterial peritonitis (SBP) prophylaxis, there is data to suggest that trimethoprim-sulfamethoxazole (TS) may be similarly effective." | 7.74 | Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. ( Angus, PW; Gow, PJ; Lontos, S; Vaughan, RB, 2008) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 7.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 7.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "Pefloxacin was used as monotherapy in 15 cases of peritonitis occurring in patients undergoing continuous ambulatory peritoneal dialysis (CAPD)." | 7.67 | [Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ( Benevent, D; Denis, F; Lagarde, C; Mounier, M, 1987) |
| " There was no difference among the studied groups regarding the incidence and severity of adverse events reported." | 6.82 | Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. ( Abdelaziz, A; Abdelrashed, M; Assem, M; El-Azab, G; Elemam, S; Elsabaawy, M; Hamed, W; Khodeer, S, 2016) |
| "Norfloxacin was not superior to other antibiotics." | 6.66 | Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. ( Fernandez, J; Ferstl, PG; Graf, C; Herrmann, E; Lange, CM; Mücke, MM; Mücke, VT; Schwarzkopf, KM; Trebicka, J; Zeuzem, S, 2020) |
| "The cumulative incidence of SBP recurrence was 28." | 5.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The SBP recurrence rate was 42." | 5.37 | Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. ( Chen, WT; Chiu, CT; Ho, YP; Huang, CH; Lin, CY; Lin, TN; Sheen, IS, 2011) |
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 5.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| "The 1-year recurrence rate of SBP can be as high as 30-70%." | 5.30 | An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. ( Ganiats, TG; McHutchison, JG; Younossi, ZM, 1997) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 5.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 5.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "Norfloxacin administration reduced the 1-year probability of developing spontaneous bacterial peritonitis (7% vs 61%, P < ." | 5.12 | Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. ( Arroyo, V; Fernández, J; Ginès, P; Monfort, D; Montoliu, S; Navasa, M; Pardo, A; Planas, R; Quintero, E; Soriano, G; Such, J; Vargas, V; Vila, C, 2007) |
| "Oral norfloxacin is the standard of therapy in the prophylaxis of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage." | 5.12 | Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. ( Arroyo, V; Durandez, R; Fernández, J; Gómez, C; Guarner, C; Navasa, M; Planas, R; Ruiz del Arbol, L; Serradilla, R, 2006) |
| "Our aim was to compare weekly rufloxacin with daily norfloxacin in the secondary prophylaxis of spontaneous bacterial peritonitis and to examine changes in antibiotic susceptibility in fecal Escherichia coli." | 5.10 | Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. ( Bauer, TM; Bory, F; Clemente, G; Follo, A; Navasa, M; Planas, R; Rodés, J; Vaquer, P; Vargas, V; Vila, J, 2002) |
| "Selective intestinal decontamination (SID) for 7 days with norfloxacin (NF) was performed in 15 patients with schistosomal hepatic fibrosis (SHF) and low-protein ascites." | 5.07 | Selective intestinal decontamination in patients with schistosomal hepatic fibrosis and low-protein ascites. ( Abou Seif Helmy, M; el Aggan, HA; el-Aggan, HA; Guirguis, TG, 1993) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 5.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "For recipients who have received prophylactic norfloxacin, clinicians should be aware of the high risk of multidrug-resistant bacterial infections during the first month after liver transplant." | 4.31 | Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period. ( Castells, L; Dopazo, C; Len, O; Lladó, L; Los-Arcos, I; Lung, M; Nuvials, X; Oriol, I; Pérez-Cameo, C; Sabé, N, 2023) |
| "Consecutively admitted patients with cirrhosis and ascitic fluid (AF) with: spontaneous bacterial peritonitis (SBP), non-infected AF, and norfloxacin as secondary SBP prophylaxis (SID group)." | 3.83 | Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis. ( Caparrós, E; Francés, R; Giménez, P; Gómez-Hurtado, I; González-Navajas, JM; Juanola, O; Moratalla, A; Piñero, P; Such, J; Zapater, P, 2016) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 3.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| " Thirty patients were taking norfloxacin or trimethoprim-sulfamethoxazole as prophylaxis against bacterial peritonitis and 11 were not." | 3.76 | Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. ( Angus, PW; Gow, PJ; Markovska, V; Skinner, N; Testro, AG; Visvanathan, K; Wongseelashote, S, 2010) |
| " The bactDNA translocation was investigated in 226 patients with cirrhosis and noninfected ascites, 22 patients with spontaneous bacterial peritonitis, and 10 patients with ascites receiving continuous norfloxacin." | 3.74 | Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. ( Bellot, P; Caño, R; Francés, R; González-Navajas, JM; Moreu, R; Muñoz, C; Pascual, S; Pérez-Mateo, M; Such, J; Zapater, P, 2008) |
| "Although norfloxacin (N) is widely accepted as the drug of choice for spontaneous bacterial peritonitis (SBP) prophylaxis, there is data to suggest that trimethoprim-sulfamethoxazole (TS) may be similarly effective." | 3.74 | Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. ( Angus, PW; Gow, PJ; Lontos, S; Vaughan, RB, 2008) |
| "The objective of the study was to examine the characteristics of spontaneous bacterial peritonitis (SBP) caused by streptococci, in particular viridans group streptococci (VGS), and to investigate a potential association between the long-term administration of norfloxacin and high-level resistance to fluoroquinolones in these organisms." | 3.73 | Viridans group streptococci: an underestimated cause of spontaneous bacterial peritonitis in cirrhotic patients with ascites. ( Bert, F; Lambert-Zechovsky, N; Noussair, L; Valla, D, 2005) |
| " Norfloxacin 400 mg per day had been introduced three months earlier as secondary prophylaxis for spontaneous bacterial peritonitis." | 3.72 | [Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin]. ( Colin, R; Di Fiore, F; Goria, O; Hervé, S; Lecleire, S; Lerebours, E; Savoye, G, 2003) |
| "Norfloxacin decreases the incidence of spontaneous bacterial peritonitis in cirrhotics, but promotes the appearance of quinolone-resistant Escherichia coli." | 3.72 | Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis. ( Cereto, F; Del Valle, O; Esteban, R; Genescà, J; González, A; Guardia, J; Molina, I, 2003) |
| "Prophylaxis with norfloxacin has been shown to be effective in preventing spontaneous bacterial peritonitis (SBP) in liver cirrhosis." | 3.71 | Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? ( Cereto, F; del Valle Ortiz, O; Esteban, R; Genescà, J; González, A; Guardia, J; Moreno, G; Smithson, A, 2002) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 3.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "We designed a prospective study to evaluate the incidence of Escherichia coli in stools at admission in patients with cirrhosis that had previously received norfloxacin as primary or secondary prophylaxis of spontaneous bacterial peritonitis (SBP) (group I, n = 28) vs those who did not (group II, n = 55)." | 3.70 | [Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination]. ( Aparicio, JR; Arroyo, A; Gutiérrez, A; Pérez-Mateo, M; Plaza, J; Such, J, 1999) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 3.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "Spontaneous bacterial peritonitis in patients with and without prophylaxis with norfloxacin are not different in clinical features, response to treatment and prognosis." | 3.69 | Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. ( Arroyo, V; Bataller, R; Cabré, E; Castells, A; Gassull, MA; Llovet, JM; Menacho, M; Moitinho, E; Navasa, M; Pardo, A; Planas, R; Rodés, J; Rodríguez-Iglesias, P, 1997) |
| "Pefloxacin was used as monotherapy in 15 cases of peritonitis occurring in patients undergoing continuous ambulatory peritoneal dialysis (CAPD)." | 3.67 | [Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ( Benevent, D; Denis, F; Lagarde, C; Mounier, M, 1987) |
| " There was no difference among the studied groups regarding the incidence and severity of adverse events reported." | 2.82 | Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. ( Abdelaziz, A; Abdelrashed, M; Assem, M; El-Azab, G; Elemam, S; Elsabaawy, M; Hamed, W; Khodeer, S, 2016) |
| "Norfloxacin was not superior to other antibiotics." | 2.66 | Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. ( Fernandez, J; Ferstl, PG; Graf, C; Herrmann, E; Lange, CM; Mücke, MM; Mücke, VT; Schwarzkopf, KM; Trebicka, J; Zeuzem, S, 2020) |
| "The cumulative incidence of SBP recurrence was 28." | 1.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo." | 1.43 | Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016) |
| "The SBP recurrence rate was 42." | 1.37 | Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. ( Chen, WT; Chiu, CT; Ho, YP; Huang, CH; Lin, CY; Lin, TN; Sheen, IS, 2011) |
| "The 1-year recurrence rate of SBP can be as high as 30-70%." | 1.30 | An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. ( Ganiats, TG; McHutchison, JG; Younossi, ZM, 1997) |
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 1.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| " The overall elimination half-life was 19." | 1.28 | Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ( Dombros, N; Nikolaidis, P; Oreopoulos, DG; Paton, TW; Tourkantonis, A; Walker, SE, 1991) |
| " This risk may depend on the dosing schedule and may be reduced by combined therapy." | 1.27 | Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. ( Auckenthaler, R; Michéa-Hamzehpour, M; Pechère, JC; Regamey, P, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.15) | 18.7374 |
| 1990's | 20 (30.77) | 18.2507 |
| 2000's | 19 (29.23) | 29.6817 |
| 2010's | 19 (29.23) | 24.3611 |
| 2020's | 3 (4.62) | 2.80 |
| Authors | Studies |
|---|---|
| Marciano, S | 2 |
| Gutierrez-Acevedo, MN | 2 |
| Barbero, S | 1 |
| Del C Notari, L | 1 |
| Agozino, M | 1 |
| Fernandez, JL | 1 |
| Anders, MM | 1 |
| Grigera, N | 1 |
| Antinucci, F | 1 |
| Orozco Ganem, OF | 1 |
| Murga, MD | 1 |
| Perez, D | 1 |
| Palazzo, A | 1 |
| Martinez Rejtman, L | 1 |
| Duarte, IG | 1 |
| Vorobioff, J | 1 |
| Trevizan, V | 1 |
| Bulaty, S | 1 |
| Bessone, F | 1 |
| Valverde, M | 1 |
| Elizondo, M | 1 |
| Bosia, JD | 1 |
| Borzi, SM | 1 |
| Stieben, TE | 1 |
| Masola, A | 1 |
| Ferretti, SE | 1 |
| Arufe, D | 1 |
| Demirdjian, E | 1 |
| Raffa, MP | 1 |
| Peralta, M | 1 |
| Fainboim, HA | 1 |
| Vazquez, CE | 1 |
| Ruiz, P | 1 |
| Martínez, JE | 1 |
| Heffner, LA | 1 |
| Odzak, A | 1 |
| Dirchwolf, M | 2 |
| Smud, A | 2 |
| Mendizabal, M | 1 |
| Bellizzi, C | 1 |
| Martinez, A | 1 |
| Tomatis, J | 1 |
| Bruno, A | 1 |
| Ramos, A | 1 |
| Pages, J | 1 |
| Tevez, S | 1 |
| Gadano, AC | 2 |
| Giunta, DH | 1 |
| Pérez-Cameo, C | 1 |
| Oriol, I | 1 |
| Lung, M | 1 |
| Lladó, L | 1 |
| Dopazo, C | 1 |
| Nuvials, X | 1 |
| Los-Arcos, I | 1 |
| Sabé, N | 1 |
| Castells, L | 1 |
| Len, O | 1 |
| Mücke, MM | 1 |
| Mücke, VT | 1 |
| Graf, C | 1 |
| Schwarzkopf, KM | 1 |
| Ferstl, PG | 1 |
| Fernandez, J | 5 |
| Zeuzem, S | 1 |
| Trebicka, J | 1 |
| Lange, CM | 1 |
| Herrmann, E | 1 |
| Yim, HJ | 1 |
| Suh, SJ | 1 |
| Jung, YK | 1 |
| Yim, SY | 1 |
| Seo, YS | 1 |
| Lee, YR | 1 |
| Park, SY | 1 |
| Jang, JY | 1 |
| Kim, YS | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Um, SH | 1 |
| Menshawy, A | 1 |
| Mattar, O | 1 |
| Barssoum, K | 1 |
| AboEl-Naga, AM | 1 |
| Salim, HM | 1 |
| Mohamed, AMF | 1 |
| Elgebaly, A | 1 |
| Abd-Elsalam, S | 2 |
| Diaz, JM | 1 |
| Bermudez, C | 1 |
| Barcán, LA | 1 |
| Giunta, D | 1 |
| Facciorusso, A | 1 |
| Papagiouvanni, I | 1 |
| Cela, M | 1 |
| Buccino, VR | 1 |
| Sacco, R | 1 |
| Wang, W | 2 |
| Yang, J | 1 |
| Liu, C | 1 |
| Song, P | 1 |
| Xu, H | 1 |
| Xia, X | 1 |
| Saffouri, GB | 1 |
| Wittich, CM | 1 |
| Lontos, S | 2 |
| Shelton, E | 1 |
| Angus, PW | 3 |
| Vaughan, R | 1 |
| Roberts, SK | 1 |
| Gordon, A | 1 |
| Gow, PJ | 3 |
| Mostafa, T | 1 |
| Badra, G | 1 |
| Abdallah, M | 1 |
| Salerno, F | 1 |
| La Mura, V | 1 |
| Assem, M | 1 |
| Elsabaawy, M | 1 |
| Abdelrashed, M | 1 |
| Elemam, S | 1 |
| Khodeer, S | 1 |
| Hamed, W | 1 |
| Abdelaziz, A | 1 |
| El-Azab, G | 1 |
| Juanola, O | 1 |
| Gómez-Hurtado, I | 2 |
| Zapater, P | 5 |
| Moratalla, A | 1 |
| Caparrós, E | 1 |
| Piñero, P | 1 |
| González-Navajas, JM | 3 |
| Giménez, P | 1 |
| Such, J | 8 |
| Francés, R | 5 |
| Machuca, J | 1 |
| Ortiz, M | 1 |
| Recacha, E | 1 |
| Díaz-De-Alba, P | 1 |
| Docobo-Perez, F | 1 |
| Rodríguez-Martínez, JM | 1 |
| Pascual, Á | 1 |
| Elfert, A | 1 |
| Abo Ali, L | 1 |
| Soliman, S | 1 |
| Ibrahim, S | 1 |
| Bert, F | 2 |
| Leflon-Guibout, V | 1 |
| Le Grand, J | 1 |
| Bourdon, N | 1 |
| Nicolas-Chanoine, MH | 1 |
| Caño, R | 3 |
| Llanos, L | 1 |
| Ruiz-Alcaraz, AJ | 1 |
| Pascual, S | 4 |
| Barquero, C | 1 |
| Moreu, R | 2 |
| Bellot, P | 3 |
| Horga, JF | 1 |
| Muñoz, C | 3 |
| Pérez, J | 1 |
| García-Peñarrubia, P | 1 |
| Pérez-Mateo, M | 5 |
| Testro, AG | 1 |
| Wongseelashote, S | 1 |
| Skinner, N | 1 |
| Markovska, V | 1 |
| Visvanathan, K | 1 |
| Huang, CH | 1 |
| Lin, CY | 1 |
| Sheen, IS | 1 |
| Chen, WT | 1 |
| Lin, TN | 1 |
| Ho, YP | 1 |
| Chiu, CT | 1 |
| Corradi, F | 1 |
| Brusasco, C | 1 |
| Vila, J | 3 |
| Ramirez, MJ | 1 |
| Seva-Pereira, T | 1 |
| Fernández-Varo, G | 1 |
| Mosbah, IB | 1 |
| Acevedo, J | 1 |
| Silva, A | 1 |
| Rocco, PR | 1 |
| Pelosi, P | 1 |
| Gines, P | 3 |
| Navasa, M | 6 |
| Pande, C | 1 |
| Kumar, A | 1 |
| Sarin, SK | 2 |
| Karakan, T | 1 |
| Tahtaci, M | 1 |
| Alagozlu, H | 1 |
| Cereto, F | 2 |
| Molina, I | 1 |
| González, A | 2 |
| Del Valle, O | 1 |
| Esteban, R | 2 |
| Guardia, J | 2 |
| Genescà, J | 2 |
| Lecleire, S | 1 |
| Di Fiore, F | 1 |
| Hervé, S | 1 |
| Goria, O | 1 |
| Savoye, G | 1 |
| Colin, R | 1 |
| Lerebours, E | 1 |
| Sandhu, BS | 1 |
| Gupta, R | 1 |
| Sharma, J | 1 |
| Singh, J | 1 |
| Murthy, NS | 1 |
| Noussair, L | 1 |
| Lambert-Zechovsky, N | 1 |
| Valla, D | 1 |
| Itha, S | 1 |
| Sharma, A | 1 |
| Bhatt, G | 1 |
| Ruiz del Arbol, L | 1 |
| Gómez, C | 1 |
| Durandez, R | 1 |
| Serradilla, R | 1 |
| Guarner, C | 4 |
| Planas, R | 5 |
| Arroyo, V | 4 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Márquez, D | 1 |
| Santana, F | 1 |
| Vaughan, RB | 1 |
| Montoliu, S | 1 |
| Monfort, D | 1 |
| Soriano, G | 3 |
| Vila, C | 1 |
| Pardo, A | 2 |
| Quintero, E | 1 |
| Vargas, V | 3 |
| Runyon, BA | 2 |
| Menon, S | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Salazar, L | 1 |
| Aller Fuente, R | 1 |
| del Olmo Martínez, L | 1 |
| de la Calle Valverde, F | 1 |
| Arranz Santos, T | 1 |
| González Hernández, JM | 1 |
| Schölmerich, J | 2 |
| Gerbes, AL | 1 |
| Andus, T | 1 |
| Leser, HG | 1 |
| Borzio, M | 1 |
| Young, S | 1 |
| Squier, SU | 1 |
| Runyon, MA | 1 |
| Castellote, J | 1 |
| Xiol, J | 1 |
| Rota Roca, R | 1 |
| Fernandez Esparrach, G | 1 |
| Dupeyron, C | 2 |
| Mangeney, N | 2 |
| Sedrati, L | 1 |
| Campillo, B | 2 |
| Fouet, P | 1 |
| Leluan, G | 2 |
| Doershuk, CF | 1 |
| Stern, RC | 1 |
| el Aggan, HA | 1 |
| el-Aggan, HA | 1 |
| Abou Seif Helmy, M | 1 |
| Guirguis, TG | 1 |
| Novella, M | 1 |
| Solà, R | 1 |
| Andreu, M | 1 |
| Gana, J | 1 |
| Ortiz, J | 1 |
| Coll, S | 1 |
| Sàbat, M | 1 |
| Vila, MC | 1 |
| Vilardell, F | 2 |
| Llovet, JM | 1 |
| Rodríguez-Iglesias, P | 1 |
| Moitinho, E | 1 |
| Bataller, R | 1 |
| Menacho, M | 1 |
| Castells, A | 1 |
| Cabré, E | 1 |
| Gassull, MA | 1 |
| Rodés, J | 3 |
| Younossi, ZM | 1 |
| McHutchison, JG | 1 |
| Ganiats, TG | 1 |
| Barrio, J | 1 |
| Castiella, A | 1 |
| López, P | 1 |
| Indart, A | 1 |
| Arenas, JI | 1 |
| Glück, T | 1 |
| Richardet, JP | 1 |
| Romero-Gómez, M | 1 |
| Suárez García, E | 1 |
| Fernández, MC | 1 |
| Jeffries, MA | 1 |
| Stern, MA | 1 |
| Gunaratnam, NT | 1 |
| Fontana, RJ | 1 |
| Aparicio, JR | 1 |
| Gutiérrez, A | 1 |
| Plaza, J | 1 |
| Arroyo, A | 1 |
| Smithson, A | 1 |
| Moreno, G | 1 |
| del Valle Ortiz, O | 1 |
| Gómez, J | 1 |
| Colmenero, J | 1 |
| Bauer, TM | 1 |
| Follo, A | 1 |
| Clemente, G | 1 |
| Bory, F | 1 |
| Vaquer, P | 1 |
| Schubert, ML | 1 |
| Sanyal, AJ | 1 |
| Wong, ES | 1 |
| Teixidó, M | 1 |
| Barrios, J | 1 |
| Enríquez, J | 1 |
| Nikolaidis, P | 1 |
| Walker, SE | 1 |
| Dombros, N | 1 |
| Tourkantonis, A | 1 |
| Paton, TW | 1 |
| Oreopoulos, DG | 1 |
| Rimola, A | 1 |
| Marco, F | 1 |
| Almela, M | 1 |
| Forné, M | 1 |
| Miranda, ML | 1 |
| Llach, J | 1 |
| Salmerón, JM | 1 |
| Hoefs, JC | 1 |
| Nord, CE | 1 |
| Edlund, C | 1 |
| Lahnborg, G | 1 |
| Pechère, JC | 2 |
| Marchou, B | 1 |
| Michéa-Hamzehpour, M | 2 |
| Auckenthaler, R | 2 |
| Regamey, P | 1 |
| Denis, F | 1 |
| Mounier, M | 1 |
| Lagarde, C | 1 |
| Benevent, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis[NCT04159870] | Phase 3 | 322 participants (Anticipated) | Interventional | 2019-11-05 | Active, not recruiting | ||
| The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy[NCT05786859] | Early Phase 1 | 124 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding[NCT00838864] | Phase 4 | 79 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis in Upper Egypt : A Prospective Hospital Based Study[NCT03163745] | 70 participants (Actual) | Observational | 2019-03-11 | Completed | |||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Patterns of Antibiotic Resistant Bacterial Infections in Liver Intensive Care Unit[NCT03855709] | 200 participants (Anticipated) | Observational | 2019-05-31 | Not yet recruiting | |||
| Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005] | Phase 2 | 104 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for norfloxacin and Peritonitis
| Article | Year |
|---|---|
Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis.
Topics: Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Multiple, Bacterial; Humans; Incidenc | 2020 |
Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis.
Topics: Antibiotic Prophylaxis; Bacterial Infections; Drug Therapy, Combination; Female; Humans; Norfloxacin | 2019 |
Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Incidence; Norfloxacin; | 2019 |
Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Humans; Network Meta-Analysis; Norfloxac | 2019 |
[Emergence of vancomycin-dependent enterococci following glycopeptide therapy: case report and review].
Topics: Bacterial Proteins; Bacteriuria; Carbon-Oxygen Ligases; Cecal Diseases; Ceftriaxone; Citrobacter fre | 2009 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
[Spontaneous bacterial peritonitis in liver cirrhosis with ascites].
Topics: Anti-Bacterial Agents; Ascites; Bacteria; Bacterial Infections; Blood; Endoscopy; Humans; Leukocyte | 1995 |
[Spontaneous bacterial peritonitis].
Topics: Animals; Ascites; Bacterial Infections; Bacterial Translocation; Cefotaxime; Diagnosis, Differential | 1998 |
16 trials available for norfloxacin and Peritonitis
| Article | Year |
|---|---|
Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Ciprofloxacin; Disease-Free Survi | 2018 |
A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial I | 2014 |
The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
Topics: Adult; Anti-Bacterial Agents; Ascites; Bacterial Infections; Female; Humans; Interleukin-10; Interle | 2015 |
Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Bacterial Infections; Drug Administration Schedule; Female; Hum | 2016 |
Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Bacterial Infections; Cause of Death; Egypt; | 2016 |
Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Cohort Studies; Cross-Over Studies; Cytokines; Fe | 2009 |
Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Bacterial Infections; Combined Modality Therapy; Do | 2012 |
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Topics: Adult; Analysis of Variance; Anti-Infective Agents; Ascites; Chi-Square Distribution; Cisapride; Dru | 2005 |
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ba | 2006 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Selective intestinal decontamination in patients with schistosomal hepatic fibrosis and low-protein ascites.
Topics: Adult; Animals; Ascites; Ascitic Fluid; Humans; Intestines; Liver Cirrhosis; Norfloxacin; Peritoniti | 1993 |
Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Drug Administration Schedule; Drug Resistance, | 1997 |
Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence.
Topics: Aged; Anti-Infective Agents; Female; Fluoroquinolones; Humans; Liver Cirrhosis; Male; Middle Aged; N | 2002 |
Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis?
Topics: Bacterial Infections; Cost-Benefit Analysis; Humans; Liver Cirrhosis; Norfloxacin; Peritonitis | 1991 |
Selective intestinal decontamination prevents spontaneous bacterial peritonitis.
Topics: Aged; Ascitic Fluid; Bacterial Infections; Female; Hospitalization; Humans; Intestines; Liver Cirrho | 1991 |
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.
Topics: Bacterial Infections; Double-Blind Method; Drug Administration Schedule; Feces; Female; Humans; Live | 1990 |
41 other studies available for norfloxacin and Peritonitis
| Article | Year |
|---|---|
Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cross-Sectional Studies; Drug R | 2023 |
Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; End Stage Liver Disease; Humans; Liver Cirrhosis | 2023 |
Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Female; Humans; Li | 2019 |
83-year-old man with abdominal swelling and lower extremity edema.
Topics: Abdominal Cavity; Aged, 80 and over; Anti-Infective Agents; Ascites; Cefotaxime; Diagnosis, Differen | 2013 |
Treatment of Spontaneous Bacterial Peritonitis.
Topics: Age Factors; Albumins; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ascites; Bilirubin; Drug Resis | 2015 |
Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis.
Topics: Adoptive Transfer; Aged; Animals; Anti-Bacterial Agents; B7-1 Antigen; B7-2 Antigen; Bacterial Infec | 2016 |
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche | 2016 |
Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Female; Gram-Negative Bacterial Infections | 2010 |
Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Liver Cirrhosis; Logistic Models; Male; | 2011 |
Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis.
Topics: Aged; Antibodies, Monoclonal; Cells, Cultured; Cyclooxygenase 2; DNA, Bacterial; Down-Regulation; Fe | 2011 |
Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Translocatio | 2012 |
Probiotics: should we be more definitive in terminology?
Topics: Bacterial Infections; Female; Humans; Male; Norfloxacin; Peritonitis; Probiotics | 2012 |
Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis.
Topics: Anti-Infective Agents; Ascitic Fluid; Drug Resistance, Bacterial; Escherichia coli Infections; Human | 2003 |
[Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Blood; Cefotaxi | 2003 |
Viridans group streptococci: an underestimated cause of spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Topics: Anti-Bacterial Agents; Ascitic Fluid; Drug Administration Schedule; Drug Resistance, Bacterial; Fema | 2005 |
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Cisapride; Drug Therapy, Combination; Gastroin | 2006 |
Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Infections; | 2007 |
Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Female; Humans; Male; Mid | 2008 |
A pill a day can improve survival in patients with advanced cirrhosis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Norflo | 2007 |
Primary prophylaxis of SBP.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Bacterial; Enteritis; Enterocoliti | 2008 |
Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; DNA, Bacterial; Female; Humans; I | 2008 |
[Spontaneous bacterial peritonitis due to Gemella morbillorum in a patient under chronic treatment with norfloxacin].
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Humans; Liver Cirrhosis, Alcoholic; Mal | 2008 |
Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis.
Topics: Administration, Oral; Animals; Carbon Tetrachloride Poisoning; Enterobacteriaceae; Enterobacteriacea | 1995 |
Spontaneous bacterial peritonitis and empyema by Escherichia coli resistant to norfloxacine in a patient on selective intestinal decontamination with norfloxacine.
Topics: Drug Resistance, Microbial; Empyema; Escherichia coli Infections; Female; Humans; Incidence; Intesti | 1994 |
Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.
Topics: Ascites; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Feces; Human | 1994 |
Spontaneous bacterial peritonitis in cystic fibrosis.
Topics: Adolescent; Adult; Bacterial Infections; Cystic Fibrosis; Female; Humans; Liver Cirrhosis; Male; Nor | 1994 |
Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Translocation; Female; Humans; Inci | 1997 |
An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis.
Topics: Anti-Infective Agents; Bacterial Infections; Cost Savings; Health Care Costs; Humans; Life Expectanc | 1997 |
[Spontaneous bacterial peritonitis caused by Streptococcus milleri in a cirrhotic patient with selective intestinal decontamination].
Topics: Aged; Anti-Infective Agents; Humans; Intestines; Liver Cirrhosis, Alcoholic; Male; Norfloxacin; Peri | 1998 |
Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Bacteremia; Cross Infection; Dru | 1998 |
Norfloxacin-induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Chemical and Drug Induced Liver Injury; Cholestasis, | 1999 |
Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Ascites; Ascitic Fluid; | 1999 |
[Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination].
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Escherichia coli; Escherichia coli Infections; | 1999 |
Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role?
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Escherichia coli; E | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Infusions, | 1991 |
Spontaneous bacterial peritonitis: prevention and therapy.
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Liver Cirrhosis; Norfloxacin; Peritonitis | 1990 |
The efficacy of pefloxacin in comparison to gentamicin in the treatment of experimentally induced peritonitis in rats.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Clo | 1986 |
Emergence of resistance after therapy with antibiotics used alone or combined in a murine model.
Topics: Amikacin; Animals; Bacteria; Bacterial Infections; Ceftriaxone; Drug Resistance, Microbial; Drug The | 1986 |
Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.
Topics: Animals; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Mice; Mice, I | 1987 |
[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics].
Topics: Adult; Aged; Anti-Infective Agents; Drug Tolerance; Humans; Kidney Failure, Chronic; Middle Aged; No | 1987 |